I'm LongbridgeAI, I can summarize articles.AEON Biopharma has appointed Paul Lee as acting chief regulatory officer via Clintrex Research. Lee, a former FDA neuroscience leader who served as deputy director of the Office of Neuroscience and led the Division of Neurology, will oversee regulatory strategy for ABP-450, a BOTOX biosimilar.
- AEON Biopharma named Paul Lee as acting chief regulatory officer through Clintrex Research. * Lee previously served at the FDA as deputy director of the Office of Neuroscience. * He also led the FDA’s Division of Neurology 2. * Role includes leading regulatory strategy for ABP-450, a biosimilar to BOTOX for therapeutic use. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here